Merck licenses 2 new compounds against HIV virus
Drugmaker Merck & Co., a pioneer in AIDS research, is licensing two experimental HIV drugs from other companies and advancing one of its own into mid-stage patient testing.
View ArticleChimerix Signs Worldwide License Agreement With Merck For CMX157, A...
Ra esearch Triangle Park, NC /PRNewswire/ -- Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide...
View ArticleMerck & Co., Inc. Licensing HIV Experimental Drugs
Drugmaker Merck & Co., a pioneer in AIDS research, is licensing two experimental HIV drugs from other companies and advancing one of its own into mid-stage patient testing.
View ArticleHow Chimerix is trying to help stem cell transplant patients
Durham-based Chimerix released data late last week highlighting the costs and risks associated with stem cell transplant patients - a problem it's looking to rectify with its new drug candidate.
View ArticleSquare 1 Financial, Inc. Announces Dr. Seth Rudnick Has Joined the Board of...
Square 1 Financial, Inc. is pleased to announce that Dr. Seth Rudnick has joined the Board of Directors of both Square 1 Financial, Inc.
View ArticleChimerix, Inc. Sets Terms for $85 Million IPO
Chimerix, a biopharmaceutical company developing oral antiviral therapeutics for CMV, announced terms for its IPO on Monday.
View ArticleChimerix could go public as early as next week
Durham drug-development company Chimerix, which could go public as early as next week, is anticipating that Wall Street will value the business at more than $300 million.
View Article6 IPOs Scheduled For The Week Of April 8th
Based in Scottsdale, AZ, Taylor Morrison Home scheduled a $500 million IPO with a market capitalization of $2 billion at a price range mid-point of $21 for Wednesday, April 10, 2013.
View ArticleTriangle could be looking at banner IPO year
In each of the past four years, just a single local company has successfully raised money from investors via an IPO.
View Article7 U.S. IPOs Planned For The Week Of April 8
Chimerix , which is developing a potent antiviral drug for use in stem cell transplants, plans to raise $85 million by offering 6.1 million shares at a price range of $13.00 to $15.00. At the midpoint...
View ArticleChimerix Expands at Meridian Corporate Center
Chimerix signed a lease renewal for its cur rent office space at 2505 Meridian Parkway in Durham, NC.
View ArticleChimerix shares rise in early trading after IPO
Shares of Chimerix Inc. are climbing after the biotech drugmaker's IPO priced at $14 per share, valuing the company's stock offering at $102.5 million.
View ArticleChimerix shares rise in early trading after IPO
A market some thought was dead now buzzes with activity, although the rising prices haven't quite returned to their peak levels Al Dutcher, Nebraska's state climatologist, said rain and snow have...
View ArticleDurham drug developer Chimerix raises $102 million in IPO
Durham drug developer Chimerix raised more than $102 million Wednesday as the 46-employee company offered its stock to Wall Street in the Triangle's second initial public offering this year.
View ArticleChimerix Stock Soars As 2 Biotechs Debut Thursday
Two biotechs, Chimerix and Omthera Pharmaceuticals , debuted on Thursday, bringing the total to five deals that have priced in April.
View ArticleChimerix adds to its IPO bounty
Chimerix, the Durham drug-development company that went public last week, said Tuesday that its underwriters exercised their option to purchase an additional 1.1 million shares of stock at the initial...
View ArticleChimerix IPO nets more than $107M for antivirals R&D
That total includes the over-allotment, the additional shares of common stock underwriters were allowed to purchase at the IPO price of $14 per share.
View ArticlePost IPO, Chimerix riding Nasdaq momentum
Durham-based drug developer Chimerix has officially completed its first week on Nasdaq, and all signs point to a great start.
View ArticleChimerix, Inc. Announces Final Study Design for Phase 3 SUPPRESS...
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! DURHAM, N.C., April 24, 2013 -- Chimerix, Inc.
View ArticleChimerix, Inc. to Present at the 12th Annual Healthcare Conference
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! DURHAM, N.C., April 26, 2013 -- Chimerix, Inc.
View Article
